ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases

NCT05265013 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision

Conditions

Head and Neck Cancer

Interventions

COMBINATION_PRODUCT: ASP-1929 Photoimmunotherapy
BIOLOGICAL: pembrolizumab

Sponsor

Rakuten Medical, Inc.